Vivacelle Bio, Inc.’s Post

We are pleased to announce that we have completed recruitment in our Phase II clinical trial of LEVI-04, a novel neurotrophin-modulating biological agent. Our founder and CSO, and study director Simon Westbrook noted, “The fact we completed recruitment in this large-scale Phase II in under a year is testament to physicians’ interest in our programme and patients’ pressing need for new treatment options for their chronic pain.” A once-a-month injectable for the treatment of osteoarthritis and chronic pain, LEVI-04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc) designed to deliver neurotrophin homeostasis. The multiple arm, multicentre, prospective, randomized, double-blind, placebo-controlled, Phase II study has enrolled more than 500 participants with pain due to osteoarthritis of the knee (ClinicalTrials.gov ID: NCT05618782). Top line data are expected to be announced in late first half of 2024. Read the news HERE https://lnkd.in/e4H-vQT3 #biotech #drugdevelopment #chronicpain #osteoarthritis #clinicaltrial

🔬New research: In a phase 1 maximal-use trial exploring the plasma pharmacokinetics, safety, and tolerability of #tirbanibulin on a 100 cm2 field, researchers presented data supporting its potential use in larger affected areas. https://lnkd.in/g5Ze3eWH

New video showing our automated liquid handler in action! 🔬 To capture single-cell drug responses in real time, we have developed an automated liquid handler for our Kinetic Image Cytometer® high content screening platform. Our liquid handler streamlines and standardizes drug treatment and image acquisition for live cells cultured in 96-well plates. It can add compounds at any point during a live-cell imaging period, making it possible to record baseline cell activity. It also has multiple drug dispensing rates to accommodate various cell types and experimental designs. Combined with CyteSeer®, our single-cell video analysis software, Vala's liquid handler can produce accurate, data-rich readouts of drug effects in high throughput. We continue to develop new live cell imaging applications, especially for hiPSC-based drug discovery models for cardiovascular and neurological diseases. Visit our website to learn more about our high content screening technology and services: https://valasciences.com/ #imaging #imagingtechnology #microscopy #highthroughput #electrophysiology #neuroscience #cardiovasculardisease #automation #drugdiscovery #drugdevelopment https://lnkd.in/epcg6j73

Our article "Amlodipine: Can act as an antioxidant in patients with transfusion-dependent β-thalassemia? A double-blind, controlled, crossover trial" was published in the Journal of Clinical Laboratory Analysis. You can see the full text of the article in the link below. https://lnkd.in/eTrhinvg #thalassemia #clinicalresearch

An exciting new research paper out on the benefits of liquid drug delivery systems thanks to Dr. Saami Yazdani, PhD, and his team at Wake Forest University. Researchers have successfully demonstrated the delivery of liquid sirolimus into the arterial wall using the FDA cleared Occlusion Perfusion Catheter (OPC), which has also shown efficacy in delivering paclitaxel below the knee with a 92% FF CDTLR at 12 months. With growing concerns regarding the safety of paclitaxel-coated balloons in peripheral artery disease use, liquid delivery of sirolimus is potentially an innovative approach to treat occluding peripheral lesions and restenosis. Read the news release. https://lnkd.in/garq3AQ2

#ACROHighlights [Featured Product] 🚀 Harnessing Cardiac Organoids for Enhanced Drug Development 🌟 Drug-induced cardiotoxicity is a significant challenge in new drug development. Due to their physiological relevance and reproducibility, cardiac organoids derived from iPSCs are now a game-changer for high-throughput drug safety screening. At ACROBiosystems, we've developed cardiac organoids that accurately predict drug-induced cardiotoxicity. But we don't stop there! Our ongoing research also covers other organoid models, including brain, liver, and intestines, to offer comprehensive support for future clinical trials. Join us at the forefront of innovation in drug development! 💊✨ 🔗https://lnkd.in/gzPuS_xg #Biotech #DrugDevelopment #CardiacOrganoids #iPSCs #ClinicalTrials

The conviction that #serendipity can be, if not systematized, at least harnessed for augmented scientific discovery, has fueled my (obviously nonlinear) professional trajectory. As we saw with Fleming's "accidental" discovery of penicillin, the #AHA moment does not happen in a vacuum: the mind needs to be ready for the discovery (or "pasteurized" for chance to favor you). While researching other examples of serendipitous drug discovery, I came across an article about systematizing serendipity for cardiovascular drug discovery. It does not fully deliver on its promise, but I can't resist sharing that it is published in AHA journals. In case you are wondering, AHA is the American Heart Association. https://lnkd.in/gWhy2fUS

BridgeBio has found success in their latest trial! Their experimental medicine, Acoramidis, (which treats the heart condition Transthyretin Amyloidosis Cardiomyopathy) consistently reduced the risk of death. In fact, 81% of patients were still alive after 30 months. Additionally, when used on patients who had been hospitalised, Acoramidis had an even stronger effect, 50% more effective than the placebo. In response, they plan to submit approval to U.S. regulators later this year. Eager to discover more about this development? Read the full article: #LifeScienceNews #FraserDove #Biotech